Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in the EU / 2025-524784-20-00
Authorised, recruiting Phase II

A Phase 2a, Open-Label Pilot Study to Evaluate the Safety/Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of VTX2735 in Participants with Recurrent Pericarditis

2025-524784-20-00 · tracked via the Priya Life Science EU tracker
Sponsor
Zomagen Biosciences Limited
Sponsor type
Pharmaceutical company
Therapeutic area
Cardiovascular Diseases
Decision date
27/02/2026
Enrollment target
32
Sites
Belgium, France, Greece, Spain, Italy

Condition studied

Recurrent Pericarditis

Eligibility

Age group
65+ years
Sex
Female, Male

Primary endpoint

Incidence and severity of AEs, SAEs, and AEs leading to study treatment discontinuation from the first dose through end of the Follow-Up Period.

Endpoint detail

Change from baseline in NRS over time through Week 6; Percent change from baseline in NRS over time through Week 6, Change from baseline in hs-CRP over time through Week 6 ; Percent change from baseline in hs-CRP over time through Week 6; Change from baseline in hs-CRP over time through Week 6 in participants with baseline CRP > 10 mg/L ; Percent change from baseline in hs-CRP over time through Week 6 in participants with baseline CRP > 10 mg/L

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-524784-20-00 on CTIS ↗ ← All trials in the EU